Propranolol for proliferative diabetic retinopathy

Andrew M. Hendrick; Jeremy Arlin Lavine; Amitha Domalpally; Amol D. Kulkarni; Michael S. Ip

doi:10.3928/23258160-20171215-05

Propranolol for proliferative diabetic retinopathy

Andrew M. Hendrick^*, Jeremy Arlin Lavine, Amitha Domalpally, Amol D. Kulkarni, Michael S. Ip

^*Corresponding author for this work

Ophthalmology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Background and Objective: To determine the effect of propranolol on retinal neovascularization due to proliferative diabetic retinopathy (PDR). Patients and Methods: For this prospective pilot, interventional, case series, patients with diabetes with PDR (n = 10 subjects; 12 eyes) were recruited at the ophthalmology clinic of the University of Wisconsin - Madison. Subjects were administered oral propranolol for 12 weeks and retinopathy and area of retinal neovascularization were monitored with fundus photography and fluorescein angiography (FA). The study's main outcome measures were photographic area of retinal neovascularization and degree of leakage on FA. Results: All eyes demonstrated stable degrees of retinal neovascularization by the end of 12 weeks. Conclusion: This dose of oral propranolol during a period of 12 weeks did not demonstrate significant effect on retinal neovascularization due to PDR.

Original language	English (US)
Pages (from-to)	35-40
Number of pages	6
Journal	Ophthalmic Surgery Lasers and Imaging Retina
Volume	49
Issue number	1
DOIs	https://doi.org/10.3928/23258160-20171215-05
State	Published - Jan 2018

Funding

Originally submitted March 21, 2017. Revision received July 25, 2017. Accepted for publication September 20, 2017. This project was supported by an unrestricted departmental grant from Research to Prevent Blindness; an Emory Ophthalmology departmental core grant (NIH/NEI: P30 EY006360); and Clinical Research FA Davis Funds, Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison. The sponsors had no role in the design or conduct of this research. Dr. Hendrick is a consultant for Clearside Biomedical. Dr. Ip is a consultant for Omeros, Thrombogenics, and Boehringer Ingelheim. The remaining authors report no relevant financial disclosures. Address correspondence to Andrew Hendrick, MD, Assistant Professor of Ophthalmology, Vitreoretinal Surgery and Diseases, 1365B Clifton Road NE, Atlanta, GA 30322; email: [email protected]. doi: 10.3928/23258160-20171215-05

ASJC Scopus subject areas

Surgery
Ophthalmology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3928/23258160-20171215-05

Cite this

@article{cc7394a3e132483791fb1fb1450da630,

title = "Propranolol for proliferative diabetic retinopathy",

abstract = "Background and Objective: To determine the effect of propranolol on retinal neovascularization due to proliferative diabetic retinopathy (PDR). Patients and Methods: For this prospective pilot, interventional, case series, patients with diabetes with PDR (n = 10 subjects; 12 eyes) were recruited at the ophthalmology clinic of the University of Wisconsin - Madison. Subjects were administered oral propranolol for 12 weeks and retinopathy and area of retinal neovascularization were monitored with fundus photography and fluorescein angiography (FA). The study's main outcome measures were photographic area of retinal neovascularization and degree of leakage on FA. Results: All eyes demonstrated stable degrees of retinal neovascularization by the end of 12 weeks. Conclusion: This dose of oral propranolol during a period of 12 weeks did not demonstrate significant effect on retinal neovascularization due to PDR.",

author = "Hendrick, {Andrew M.} and Lavine, {Jeremy Arlin} and Amitha Domalpally and Kulkarni, {Amol D.} and Ip, {Michael S.}",

note = "Funding Information: Originally submitted March 21, 2017. Revision received July 25, 2017. Accepted for publication September 20, 2017. This project was supported by an unrestricted departmental grant from Research to Prevent Blindness; an Emory Ophthalmology departmental core grant (NIH/NEI: P30 EY006360); and Clinical Research FA Davis Funds, Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison. The sponsors had no role in the design or conduct of this research. Dr. Hendrick is a consultant for Clearside Biomedical. Dr. Ip is a consultant for Omeros, Thrombogenics, and Boehringer Ingelheim. The remaining authors report no relevant financial disclosures. Address correspondence to Andrew Hendrick, MD, Assistant Professor of Ophthalmology, Vitreoretinal Surgery and Diseases, 1365B Clifton Road NE, Atlanta, GA 30322; email: [email protected]. doi: 10.3928/23258160-20171215-05",

year = "2018",

month = jan,

doi = "10.3928/23258160-20171215-05",

language = "English (US)",

volume = "49",

pages = "35--40",

journal = "Ophthalmic Surgery Lasers and Imaging Retina",

issn = "2325-8160",

publisher = "Slack Incorporated",

number = "1",

}

TY - JOUR

T1 - Propranolol for proliferative diabetic retinopathy

AU - Hendrick, Andrew M.

AU - Lavine, Jeremy Arlin

AU - Domalpally, Amitha

AU - Kulkarni, Amol D.

AU - Ip, Michael S.

N1 - Funding Information: Originally submitted March 21, 2017. Revision received July 25, 2017. Accepted for publication September 20, 2017. This project was supported by an unrestricted departmental grant from Research to Prevent Blindness; an Emory Ophthalmology departmental core grant (NIH/NEI: P30 EY006360); and Clinical Research FA Davis Funds, Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison. The sponsors had no role in the design or conduct of this research. Dr. Hendrick is a consultant for Clearside Biomedical. Dr. Ip is a consultant for Omeros, Thrombogenics, and Boehringer Ingelheim. The remaining authors report no relevant financial disclosures. Address correspondence to Andrew Hendrick, MD, Assistant Professor of Ophthalmology, Vitreoretinal Surgery and Diseases, 1365B Clifton Road NE, Atlanta, GA 30322; email: [email protected]. doi: 10.3928/23258160-20171215-05

PY - 2018/1

Y1 - 2018/1

N2 - Background and Objective: To determine the effect of propranolol on retinal neovascularization due to proliferative diabetic retinopathy (PDR). Patients and Methods: For this prospective pilot, interventional, case series, patients with diabetes with PDR (n = 10 subjects; 12 eyes) were recruited at the ophthalmology clinic of the University of Wisconsin - Madison. Subjects were administered oral propranolol for 12 weeks and retinopathy and area of retinal neovascularization were monitored with fundus photography and fluorescein angiography (FA). The study's main outcome measures were photographic area of retinal neovascularization and degree of leakage on FA. Results: All eyes demonstrated stable degrees of retinal neovascularization by the end of 12 weeks. Conclusion: This dose of oral propranolol during a period of 12 weeks did not demonstrate significant effect on retinal neovascularization due to PDR.

AB - Background and Objective: To determine the effect of propranolol on retinal neovascularization due to proliferative diabetic retinopathy (PDR). Patients and Methods: For this prospective pilot, interventional, case series, patients with diabetes with PDR (n = 10 subjects; 12 eyes) were recruited at the ophthalmology clinic of the University of Wisconsin - Madison. Subjects were administered oral propranolol for 12 weeks and retinopathy and area of retinal neovascularization were monitored with fundus photography and fluorescein angiography (FA). The study's main outcome measures were photographic area of retinal neovascularization and degree of leakage on FA. Results: All eyes demonstrated stable degrees of retinal neovascularization by the end of 12 weeks. Conclusion: This dose of oral propranolol during a period of 12 weeks did not demonstrate significant effect on retinal neovascularization due to PDR.

UR - http://www.scopus.com/inward/record.url?scp=85040467872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040467872&partnerID=8YFLogxK

U2 - 10.3928/23258160-20171215-05

DO - 10.3928/23258160-20171215-05

M3 - Article

C2 - 29304264

AN - SCOPUS:85040467872

SN - 2325-8160

VL - 49

SP - 35

EP - 40

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

IS - 1

ER -

Propranolol for proliferative diabetic retinopathy

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this